All In Biotech

Drug Trial Radar · NCT05118776

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma

Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

136

Actual

Start

Jan 21, 2022

Primary completion

Jun 2025

Study completion Jun 2025

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.

Conditions

  • Recurrent Glioblastoma

Interventions

  • ASC40 tabletsDrug

    ASC40 tablets administered orally once daily

  • Placebo tabletsDrug

    Placebo administered orally once daily.

  • BevacizumabDrug

    Bevacizumab once every 2 weeks, intravenous drip.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
  2. Total survivalTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital,Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.